Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073166 | 0.72 | APP (0.52) | — | |
| SCHEMBL13473561 | 0.71 | JAK3 (0.32) | FFAR2 | |
| SCHEMBL10073641 | 0.70 | BRD4 (0.39) | — | |
| SCHEMBL10072925 | 0.69 | ALDH1A1 (0.50) | FFAR2 | |
| SCHEMBL12243451 | 0.69 | ADAM17 (0.32) | — | |
| SCHEMBL10072915 | 0.69 | — | — | |
| SCHEMBL10072938 | 0.68 | ALOX5AP (0.41) | — | |
| SCHEMBL10073463 | 0.68 | ALDH1A1 (0.32) | FFAR2 | |
| SCHEMBL13473504 | 0.67 | TBXA2R (0.32) | — | |
| SCHEMBL10072900 | 0.67 | HSD11B1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445681-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | PRKDC, MAP3K20, PRKACA | FFAR2 4329/4885DPP4 2369/4885P2RX7 2002/4885 |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | PRKDC, MAP3K20, PRKACA | FFAR2 4329/4885DPP4 2369/4885P2RX7 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.